Chloe Meadows so ‘scared' she ignored ulcerative colitis symptoms for a decade
The former star of The Only Way Is Essex, 33, first discovered blood in her stool, a symptom of ulcerative colitis, when she was 16
The Only Way is Essex star Chloe Meadows
(Image: Getty Images for Amazon MGM Stud )
Reality TV star Chloe Meadows has said she was so "scared" of the doctors and the prospect of "having any procedure done" that she ignored symptoms of a chronic inflammatory bowel condition for around 10 years.
The former star of The Only Way Is Essex, 33, first discovered blood in her stool, a symptom of ulcerative colitis, when she was 16.
"I went to a college where I boarded when I was 16. I was staying away from home and I was living in a student house and there was blood down the toilet", she told Dr Oscar Duke's Bedside Manners podcast.
"I remember I told my mum and I was like, there's quite a lot of blood down the toilet. I'm not really sure what's going on.
"She was of course like, go to the doctors. I went to the doctors, and they said that I would have to have a colonoscopy, which is a camera into the bowel."
Meadows added: "At this point in my life, I had never really ever been to the hospital. I'd never been sick.
Article continues below
"I'd never had any procedure or operation. I'd never been sedated. I'd never had anything and the doctor referred me and I got this letter, and this is awful, but I got this letter and I just never went to the appointment because I was terrified.
"Then I ignored it and what would happen, which is what I realise now, is that I can go into remission, I can go into a flare-up in remission.
"It would stop for periods of time so that the blood would go away. I'd be like, 'Oh, cool, it's gone away, I'm better. There's nothing wrong with me'.
"I'd go through years where it wouldn't happen and then it would happen again, and then it would stop again.
"I would probably lie to my mum about how much it would happen because she always pestered me about it and I was like, 'No, it's fine'.
"I just got on with it and ignored it. I think I was scared of having any procedure done.
"I was also scared of what they were going to tell me ... I was just terrified, which is not really a reason not to go to the doctor, but I think that's just what I thought.
"I was young as well, so I would forget when there wasn't blood down the toilet, I would completely forget."
Ulcerative colitis is a long-term condition where the colon and rectum become inflamed, according to the NHS website.
Symptoms include recurring diarrhoea, which may contain blood, extreme tiredness, loss of appetite and weight loss.
Meadows said she had some health checks aged 26, 10 years after her symptoms first appeared, after she went on a diet at a time where she was also losing a lot of blood.
Her mother intervened and said she should go to the doctors and get a blood test as she looked "grey".
While she was out filming, after she had the blood tests, Meadows received a number of missed calls from her father who then texted her to say a doctor had advised her she should got straight to A&E because her "blood was so low".
"I went to the hospital. I had to have all of these checks and these iron infusions and that was where it started," she said.
Meadows also revealed that she had "probably my longest flare-up" after filming a nerve wracking scene on Towie.
Article continues below
Some people with ulcerative colitis may go for weeks or months with very mild symptoms, or none at all (remission), followed by flare-ups and relapses, according to the NHS website.
Treatment options include corticosteroids, immunosuppressants and surgery.
Charity Crohn's And Colitis UK says there are more than 300,000 people in the UK living with colitis.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Record
28 minutes ago
- Daily Record
Common painkiller linked to deadly heart failure in older people
A major study found pregabalin raises heart failure risk, especially in older patients with heart disease. A widely prescribed drug for nerve pain, anxiety and epilepsy has been linked to a significantly higher risk of heart failure, prompting calls for doctors to be more cautious when offering it to certain patients. Pregabalin, available on prescription in the UK, was associated with a 48 percent increased risk of developing heart failure, according to a major new study. The risk was even greater among those with an existing history of heart disease, rising to 85 percent compared with patients prescribed gabapentin, a similar medication used for nerve pain. The research, led by Columbia University Irving Medical Centre, examined the records of 246,237 Medicare patients aged between 65 and 89 over a four-year period. All participants had chronic non-cancer pain lasting longer than 12 weeks and none had previously been diagnosed with heart failure. Heart failure occurs when the heart is unable to pump enough blood to meet the body's needs. While it can affect people at any age, it becomes more common as people grow older due to natural weakening and stiffening of the heart muscle. During the study period, 1470 participants were admitted to hospital with heart failure. Researchers calculated that for every 1000 people taking pregabalin, there were around six additional cases each year compared with those not on the drug. Dr Elizabeth Park, who led the study, said the findings supported the European Medicines Agency's current advice for doctors to be cautious when prescribing pregabalin to older adults with heart disease. 'Doctors should consider the cardiovascular risks of pregabalin, particularly for older or vulnerable patients,' the researchers said in their conclusion. Pregabalin works by altering the way nerves send messages to the brain and is often used when traditional painkillers fail to relieve nerve pain. While generally considered safe under medical supervision, the drug can cause side effects including headaches, diarrhoea, nausea, blurred vision and memory problems. In rare instances, pregabalin can trigger a severe allergic reaction known as anaphylaxis. The NHS advises that pregabalin is only suitable for adults and may not be appropriate for people over 65. It should not be given to children under 18. Doctors are advised to check whether patients have ever had an allergic reaction to pregabalin or any other medication, a history of substance misuse, or are pregnant or breastfeeding before prescribing the drug. People on a controlled sodium diet, or those with kidney problems, are also advised to consult their doctor, as some liquid formulations contain sodium. Join the Daily Record WhatsApp community! Get the latest news sent straight to your messages by joining our WhatsApp community today. You'll receive daily updates on breaking news as well as the top headlines across Scotland. No one will be able to see who is signed up and no one can send messages except the Daily Record team. All you have to do is click here if you're on mobile, select 'Join Community' and you're in! If you're on a desktop, simply scan the QR code above with your phone and click 'Join Community'. We also treat our community members to special offers, promotions, and adverts from us and our partners. If you don't like our community, you can check out any time you like. To leave our community click on the name at the top of your screen and choose 'exit group'. If you're curious, you can read our Privacy Notice. Patients with breathing difficulties should also inform their healthcare provider before starting treatment. Although there is no cure for heart failure, recognising symptoms early can help slow its progression and improve quality of life. Common signs include shortness of breath during activity or when lying down, fatigue, and swelling in the legs, ankles and feet. Other symptoms can include a persistent cough, rapid or irregular heartbeat, dizziness and fainting. Experts say prevention is key to reducing the likelihood of heart failure. Maintaining a healthy weight, staying physically active, eating a balanced diet, avoiding smoking, and controlling conditions such as high blood pressure, high cholesterol and diabetes can all help lower the risk.
Daily Mail
28 minutes ago
- Daily Mail
Lorraine star reveals GP son was held at knifepoint in 'terrifying' ordeal at work - pleading 'it needs to stop' and begging for 'more protection'
A Lorraine star has revealed his GP son was held at gunpoint during a 'terrifying' ordeal while at work - and begged for more protection for frontline NHS workers. Dr Hilary Jones has been the daytime programme's health editor for an impressive 15 years - frequently appearing to offer medical advice and debunk health myths. But the 72-year-old has now offered a rare and candid glimpse into his life - telling how his son was threatened with a knife while on duty. On Monday morning's installment of the show, host Ranvir Singh began: 'You've spoken in an interview with a newspaper about something that happened to your son, who is a GP. 'Not recently, but it's, obviously, for any father - what happened to your son as a GP was terrifying.' Dr Hilary explained: 'So, he's conducting a GP surgery and a patient leans over the desk brandishing a knife - threatening him with a knife. 'Now, he dealt with it really well, he's fine, but this is not an isolated incident.' The concerned father told how one in six NHS workers and one in three ambulance staff in England have been abused physically. Dr Hilary also highlighted that a staggering ten percent of nurses have been sexually harassed by visitors or patients. 'It's something that has to stop,' he continued. 'It's basically an abuse of the NHS.' 'In 1948, when the NHS was created, everyone was so in love with it and so grateful - this never happened. 'But now it's as if people go, "We can just abuse those staff. They're here at our request and will do anything that we want them to do, and we can threaten them if they don't do it."' Dr Hilary went on to say that doctors need 'more protection' and 'better reporting systems' to keep them safe at work. It follows Dr Hilary's return to the studio after major surgery and weeks off screen. During last week's installment of Lorraine, step-in host Christine Lampard, 46, pointed out his return and said: 'Now, welcome back. 'I feel like there should be a big round of applause for this. Dr Hilary is back in the studio. 'It's so lovely to see you because you've been off. You've had a little op!' Dr Hilary replied: 'I had a little operation on my hip. Yes I had a hip replacement five weeks ago, tomorrow.' 'Hip replacement surgery - sometimes called total hip replacement - involves replacing damaged parts of your hip joint with metal, plastic or ceramic parts,' the NHS states. It is commonly done to 'treat pain and stiffness in the hip joint'. Dr Hilary continued: 'Look it's great to be back with my extended family. I've missed you guys!' 'Well you're looking great,' Christine told him. Dr Hilary replied: 'Well I'm feeling great. There I was... that was the day after I had my hip replacement. It's such a good operation. 'I think people tend to leave it too long. They are in a lot of pain for a long time with limited mobility and that mans their muscles become weaker. 'So rehabilitation takes longer. I was very lucky to have this done on the NHS. Wonderful treatment. I had a spinal anesthetic so I was semi conscious during the procedure.'
The Guardian
an hour ago
- The Guardian
Off-the-shelf vaccine shows promise in preventing cancers returning, study finds
An off-the-shelf vaccine has shown promise in preventing the return of pancreatic and colorectal cancer, researchers have revealed. Cancer vaccines have been the subject of promising research in recent years. The NHS in England has been trialling various jabs in patients through the Cancer Vaccine Launch Pad (CVLP). Such vaccines train the body's immune system to recognise cancer cells so any that return after treatments such as surgery can be hunted down and killed, reducing the risk of the disease coming back. Many cancer vaccines, including some of those based on mRNA technology, are personalised to the patient's tumours. However, a study has suggested a non-personalised, experimental vaccine that is already being made at scale could help prevent the return of pancreatic and colorectal cancer. If borne out by further trials, experts say, the approach could be beneficial since the vaccine is likely to be cheaper and faster to access than mRNA jabs, as well as less toxic than some other therapies. 'After a long-term follow-up of this study, we were able to demonstrate that the group of patients who mounted an immune response have a greater likelihood of not having their cancer return and living longer compared to historical expectation of what that patient would do,' said Prof Zev Wainberg, an oncologist at the University of California, Los Angeles, and a co-author of the study. The authors noted 90% of people with pancreatic cancer and 50% of those with colorectal cancer had mutations in the Kras gene. These mutations result in the production of altered Kras proteins that cause cells to divide and proliferate. Writing in the journal Nature Medicine, Wainberg and colleagues reported how they gave a vaccine called ELI-002 2P to 20 patients who had had surgery for pancreatic cancer and five who had been operated on for colorectal cancer. The vaccine contains peptides – long chains of amino acids, which are the building blocks of proteins. The vaccine works by training the T-cells of the body's immune system to recognise and kill cancer cells with mutations that result in them producing the altered Kras proteins. At a median follow-up of almost 20 months, the team found patients fell into two groups: 17 who had a strong immune response to the jab and eight who had a weaker response. The team found the former group experienced a longer period before their cancer returned and survived longer overall. Overall, four of those 17 patients died during follow-up, compared with seven of the eight who had a lower immune response. However, the study is early stage research designed primarily to assess safety, involved only 25 participants, had no controls, and looked at two very different types of cancer. Even so, experts said the results were worth noting. Siow Ming Lee, a professor of medical oncology at University College London, who was not involved with the work, suggested the ELI-002 2P vaccine could be combine with other kinds of immunotherapy, and might help a wider range of patients. 'With promising early results and potentially fewer side-effects than current oral inhibitors, this off-the-shelf cancer vaccine could expand treatment options for Kras-driven cancers and warrants further testing in larger trials, including exploring its potential use in lung cancers driven by mutations in Kras gene,' he said. Dr Shivan Sivakumar of the University of Birmingham, who works on mRNA-based pancreatic cancer vaccines, said it was fascinating so many of the patients in the study showed a clear immune response to the off-the-shelf vaccine. But Sivakumar noted that a key advantage of personalised mRNA vaccines was that they did not have to rely on mutations in the Kras gene. He said it was now important to carry out randomised control trials of the ELI-002 2P vaccine and follow patients over a longer period. 'How many times have we been down this garden path where we've got really excited about the science? But actually, ultimately, the real scientific experiment is in patients,' Sivakumar added.
